iPS Cells for Modelling and Treatment of Retinal Diseases
AbstractFor many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Chen, F.K.; McLenachan, S.; Edel, M.; Da Cruz, L.; Coffey, P.J.; Mackey, D.A. iPS Cells for Modelling and Treatment of Retinal Diseases. J. Clin. Med. 2014, 3, 1511-1541.
Chen FK, McLenachan S, Edel M, Da Cruz L, Coffey PJ, Mackey DA. iPS Cells for Modelling and Treatment of Retinal Diseases. Journal of Clinical Medicine. 2014; 3(4):1511-1541.Chicago/Turabian Style
Chen, Fred K.; McLenachan, Samuel; Edel, Michael; Da Cruz, Lyndon; Coffey, Peter J.; Mackey, David A. 2014. "iPS Cells for Modelling and Treatment of Retinal Diseases." J. Clin. Med. 3, no. 4: 1511-1541.